Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 10/20 | 0.46 |
| ▸ | TDO2 | P48775 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | CDK8 | P49336 | 2/20 | 0.41 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2517447 | 1.00 | IDO1 (0.46) | IDO1TDO2KITKDRFLT3 | |
| SCHEMBL2517446 | 1.00 | IDO1 (0.46) | IDO1TDO2KITKDRFLT3 | |
| SCHEMBL21118141 | 0.87 | KDR (0.49) | IDO1TDO2KDRFLT3IKBKE | |
| SCHEMBL21118296 | 0.86 | IDO1 (0.50) | IDO1TDO2 | |
| SCHEMBL2516716 | 0.86 | IDO1 (0.50) | IDO1TDO2 | |
| SCHEMBL2516714 | 0.86 | IDO1 (0.50) | IDO1TDO2 | |
| SCHEMBL4368291 | 0.85 | GRM4 (0.44) | IDO1KITKDRFLT3GRM4 | |
| SCHEMBL4368296 | 0.85 | GRM4 (0.44) | IDO1KITKDRFLT3GRM4 | |
| SCHEMBL12054227 | 0.84 | KDR (0.44) | IDO1TDO2KITKDRFLT3 | |
| SCHEMBL149916 | 0.82 | IDO1 (0.62) | IDO1TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2022-01-04 | — | — | US | disclosed |
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | NANJING HUAWE MEDICINE TECHNOLOGY GROUP CO., LTD. (CN) | 2021-04-01 | — | — | US | disclosed |
| WO-2019141027-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, PREPARATION METHOD THEREOF AND USE THEREOF | 南京华威医药科技集团有限公司 | 2019-07-25 | — | — | WO | disclosed |
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | SHANDONG LUYE PHARMACEUTICAL CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210094924-A1 | INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR, METHOD FOR PREPARATION AND USE THEREOF | IDO1, IDO2, KYNU | IDO1 1/4885TDO2 6/4885KIT 1123/4885 |
| US-20190169140-A1 | IDO1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | IDO1, IDO2, INMT | IDO1 1/4885TDO2 5/4885KIT 354/4885 |
| US-11214554-B2 | Indoleamine 2,3-dioxygenase inhibitor, method for preparation and use thereof | IDO1, IDO2, KYNU | IDO1 1/4885TDO2 6/4885KIT 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.